Development of new imidazopyridine-based chalcones hybrids as potent antidiabetic and antioxidant agents: synthesis, in silico and in vitro evaluation Authors: Hanan Abdelmawgoud Atia, Aladdin M. Srour, Hanaa Farag, Wael Mahmoud Aboulthana, Abdulrahman M. Saleh, Mohamed Gamal Thabit, Ranza Elrayess, Asmaa Saleh, Jarosław Dziadek, Ahmed Sabt Published: 2026 ABSTRACT Nowadays, diabetes mellitus (DM) is a rapidly growing global health concern. In this study, we synthesized a novel series of six imidazopyridine-based chalcone hybrids (5a-f) and evaluated their in vitro biological activities, including total antioxidant capacity, iron-reducing power, and radical scavenging (DPPH, ABTS, NO), as well as antidiabetic potential against α-amylase, α-glucosidase, and aldose reductase. All compounds showed moderate to potent activity, with derivatives 5c and 5f being the most effective. Compound 5f exhibited the highest antioxidant performance (total capacity: 78.63 mg GAE/g; reducing power: 68.88 µg/ml) and strong radical scavenging (IC50: 5.68, 4.75, and 6.52 µg/ml for DPPH, ABTS, and NO, respectively), comparable to ascorbic acid. It also potently inhibited α-amylase, α-glucosidase, and aldose reductase (IC50: 6.71, 4.78, and 4.04 µg/ml). Molecular docking and 100 ns MD simulations further supported these findings: compound 5f showed the best aldose reductase binding (–8.97 kcal/mol), outperforming reference IDD594, while 5c bound favorably to α-amylase and α-glucosidase (–7.28 and − 6.64 kcal/mol) through π-interactions, ionic contacts, and key hydrogen bonds. The 5f-aldose reductase complex remained stable throughout the simulation, with maintained active-site and loop conformations after minor early fluctuations.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1038/s41598-026-62643-8. Introduction Diabetes mellitus (DM) comprises a group of chronic metabolic disorders unified by persistent hyperglycemia and dysregulated carbohydrate, lipid, and protein metabolism. This systemic dysfunction arises from an absolute or relative deficiency in insulin action, secretion, or both. These conditions are primarily categorized into two distinct etiologies: Type 1 (T1DM) and Type 2 (T2DM)1. T1DM is characterized by autoimmune destruction of insulin-producing pancreatic β-cells, often driven by autoreactive T lymphocytes that infiltrate the pancreatic islets. This results in severe hypoinsulinemia and a subsequent loss of glycemic control. In contrast, T2DM is a multifactorial condition defined by systemic insulin resistance and progressively impaired insulin secretion, leading to a chronic state of metabolic imbalance2. A critical therapeutic strategy in the management of T2DM involves the regulation of postprandial glucose levels through the modulation of carbohydrate-digesting enzymes, specifically α-amylase and α-glucosidase3. These enzymes play a pivotal role in the glycemic index of dietary intake by catalyzing the hydrolysis of α-(1→4) glycosidic linkages in complex polysaccharides and oligosaccharides. This enzymatic breakdown accelerates the conversion of starch and polyglycans into absorbable monosaccharides, which are then rapidly released into the bloodstream, triggering sharp increases in blood glucose levels4. Aldose reductase is a cytosolic, NADPH-dependent oxidoreductase responsible for catalyzing the reduction of glucose to sorbitol, which constitutes the initial step in the polyol metabolic pathway. In addition, it is believed to be involved in diabetic retinopathy, and variations (polymorphisms) in the aldose reductase gene have been linked to the speed at which retinopathy progresses in individuals with diabetes; therefore, Inhibition of this enzyme has been pursued as a therapeutic strategy to prevent or slow the onset and progression of chronic diabetic complications, regardless of blood glucose levels. However, numerous aldose reductase inhibitors that have been developed demonstrated limited clinical efficacy, adverse effects, and unfavorable pharmacokinetic profiles in trials. To date, epalrestat remains the only commercially available aldose reductase inhibitor5. While α-amylase is primarily synthesized in the pancreas and secreted into the small intestine to initiate the breakdown of long-chain starch molecules, α-glucosidase is localized within the brush-border epithelial cells of the small intestine to complete the final stage of digestion. The synergistic activity of these two enzymes is a primary determinant of postprandial hyperglycemic spikes. Consequently, the development of potent inhibitors targeting these enzymes remains a cornerstone of pharmacological research, as mitigating the rate of glucose absorption offers a viable pathway to reducing the risk of long-term diabetic complications6,7. A widely adopted therapeutic strategy involves inhibiting the carbohydrate-hydrolyzing enzymes α-glucosidase and α-amylase, thereby delaying carbohydrate digestion and reducing the rate of glucose absorption into the bloodstream6,7. Several therapeutic agents, such as Acarbose I and Quercetin-based compounds II, have been used to reduce the activity of these enzymes8,9. The pressing need for novel antidiabetic drugs stems from the rising global prevalence of Type 2 Diabetes (T2DM), the limited success of current therapies in achieving optimal glycemic control for every patient, and the growing demand for treatments with milder side-effect profiles. The imidazopyridine nucleus represents a significant class of fused, nitrogen-containing heterocycles, widely recognized as privileged scaffolds in medicinal chemistry. These motifs are highly valued for their versatile pharmacological profiles and their ability to serve as purine mimics in biological systems10. Imidazopyridine derivatives exhibit a broad spectrum of biological activities, most notably as potent anticancer agents that target various kinase pathways to inhibit tumor growth. Beyond oncology, this scaffold is extensively explored for its antimicrobial, antiviral, and anti-inflammatory potential, making it a cornerstone for the development of novel therapeutic agents11, insecticidal activity12, Zika viral infection inhibitors13, antimicrobial14, antitubercular agents15, and treatment of Alzheimer’s disease16. Imidazopyridine scaffolds have attracted considerable interest in the field of medicinal chemistry owing to their prevalent presence in numerous marketed pharmaceuticals and drug candidates, such as Zolpidem (III), a sedative and hypnotic agent, and Saripidem (IV) an anxiolytic agent17. Recently, imidazopyridine derivatives have emerged as promising and potent synthetic heterocyclic compounds being investigated for their potential as anti-diabetic agents18. Li and colleagues identified the imidazopyridine scaffold as a promising inhibitor of the enzymes dipeptidyl-peptidase 4 (DPP-4) and glycogen synthase kinase-3 beta (GSK3β), demonstrating compound V, with an IC50 value of 0.13 µM19. Also, in 2020, Saeedi et al. described the design and synthesis of a series of imidazo[1,2-a]pyridine derivatives conjugated with a carbamate moiety to evaluate their potential anti-diabetic effects through the inhibition of the α-glucosidase enzyme. Among these compounds, compound VI demonstrated the highest activity, exhibiting a promising inhibitory effect with an IC50 value of 75.6 µM20. In addition, Rasheed et al. demonstrated that compound VII exhibits antidiabetic properties by inhibiting the α-glucosidase enzyme, with an IC50 value of 5.57 µg, Fig. 121, . Chalcones are a prominent subgroup of the flavonoid family, defined by a core structure of two aromatic rings linked by a three-carbon α,β-unsaturated carbonyl moiety. This open-chain scaffold serves as a versatile biosynthetic precursor for more complex flavonoids and is recognized as a privileged motif in medicinal chemistry22–24. The electrophilic enone system allows chalcones to act as Michael acceptors, facilitating interactions with diverse biological targets25. Consequently, chalcone derivatives exhibit a broad spectrum of pharmacological activities, including anticancer, anti-inflammatory, antioxidant, and antidiabetic effects. Their structural simplicity and synthetic flexibility make them ideal frameworks for the development of targeted bioactive agents23–25. Moreover, Researchers have also found chalcones to have highly effective anti-diabetic activity26,27. A novel chalcone derivative VIII was developed by Kaewin et al., capable of activating AMPK in vitro and in vivo and exhibiting efficacy against hyperglycemia and DN in mice28. Furthermore, other chalcone derivatives (IX and X) displayed significant activity as antidiabetic agents by suppressing the α-glucosidase enzyme29,30. Pyridine and its derivatives represent highly promising and novel antidiabetic agents, especially in the management of type 2 diabetes via multi-targeted mechanisms31,32. For instance, the pharmacological significance of pyridine derivatives (XI and XII) has been investigated concerning their antidiabetic activities, Fig. 133,34, . Fig. 1Representative chemical structures of previously reported anti-diabetic agents and the newly synthesized compounds 5a-f. The figure highlights bioactive scaffolds including imidazopyridine derivatives (III-VII), chalcone derivatives (VIII-X), and pyridine-based components (XI-XII). The bottom section illustrates the target molecules 5a-f developed in this study. Representative chemical structures of previously reported anti-diabetic agents and the newly synthesized compounds 5a-f. The figure highlights bioactive scaffolds including imidazopyridine derivatives (III-VII), chalcone derivatives (VIII-X), and pyridine-based components (XI-XII). The bottom section illustrates the target molecules 5a-f developed in this study. Building upon these well-established bioactive scaffolds, we rationally designed and synthesized a novel series of imidazopyridine-chalcone and pyridine derivatives with the aim of identifying potent antioxidant and antidiabetic agents. The biological activities of the synthesized hybrids were subsequently evaluated through a range of relevant in vitro antioxidant and antidiabetic assays. To further elucidate their molecular mechanism of action, molecular docking and molecular dynamics (MD) simulations were performed, providing detailed insights into the binding interactions and conformational stability of the most promising compounds within the active site of the target enzyme. Results and discussion Chemistry Scheme 1 illustrates the synthetic pathways employed to obtain the target hybrid molecules (5a-f). As illustrated, the synthesis commenced with the copper bromide-catalyzed condensation of 2-aminopyridine (1) with various cinnamaldehyde derivatives (2a-f) in refluxing ethanol, yielding the key bicyclic intermediates, imidazo[1,2-a]pyridine carboxaldehyde derivatives (3a-f). These aldehyde intermediates were subsequently subjected to a base-catalyzed Claisen-Schmidt condensation with 2-acetylpyridine (4) at room temperature in ethanol using potassium hydroxide, successfully providing the final hybrid chalcone derivatives (5a-f). The structures of these newly synthesized chemical entities were confirmed and characterized by thorough spectral analysis, including 1H and 13C NMR, mass spectrometry (MS), and elemental analysis. The successful formation of the α,β-unsaturated carbonyl (chalcone) framework linking the imidazopyridine and pyridine cores was definitively established by diagnostic signals in both the 1H and 13C NMR spectra. In the 1H NMR spectra, the successful incorporation of specific substituent groups was verified by distinct diagnostic peaks; for instance, the methyl protons of derivative 5b appeared as a sharp singlet at δH = 2.39 ppm (with a corresponding carbon peak at δC = 20.13 ppm), while the methoxy (-OCH3) group of 5e was confirmed by a carbon signal at δC = 55.27 ppm. The 13C NMR spectra revealed that the resonance of the carbonyl carbon (C = O) appeared characteristically downfield at δC = 187.79-188.02 ppm. Furthermore, the core framework was verified by the presence of characteristic imidazo[1,2-a]pyridine and pyridine C = N carbons appearing in the range of δC = 156.45-156.53 ppm and 159.21-159.51 ppm, respectively. Scheme 1The synthetic route for the preparation of Imidazopyridine-chalcone-Pyridine derivatives 5a-f. The synthetic route for the preparation of Imidazopyridine-chalcone-Pyridine derivatives 5a-f. Biological evaluations In vitro Antioxidant activity The biological properties of these synthetic derivatives, such as their anti-diabetic, antioxidant, and radical scavenging properties, were evaluated and compared with the reference drug in each test. Both compounds 5c and 5f demonstrated similar TAC and IRP values, followed by compound 5d (58.05 ± 0.87 mg gallic acid/g and 48.30 ± 0.87 µg/mL, respectively), and compounds 5a (45.09 ± 0.12 mg gallic acid/g and 35.34 ± 0.12 µg/mL, respectively). In addition, Compounds 5c and 5f exhibited excellent antioxidant activity. The superior performance of Compound 5c is attributed to the presence of free chloro (4-Cl) groups, which enhance the molecule’s structural ability to neutralize free radicals through mechanisms like hydrogen atom donation or electron transfer, rather than direct scavenging35. Additionally, the antioxidant activity of compound 5f is attributed to the presence of a free nitro (-NO2) group, which donates electrons or hydrogen atoms to counteract free radicals and interrupt oxidative chain reactions. The -NO2 group serves as an electron-withdrawing agent, increasing the stability of scavenging sites and enhancing antioxidant efficacy36. Conversely, Compounds 5b and 5e exhibited the lowest TAC and IRP values at the same concentration. This is attributed to the presence of 4-methyl (4-CH3) and 4-methoxy (4-OCH3) substitutions on phenolic aromatic rings. These substitutions exhibit lower antioxidant activity compared to other patterns due to steric hindrance and the impact of the substituent on radical stabilization37. Among the evaluated compounds, the standard ascorbic acid exhibited the most potent antioxidant activity, with a Total Antioxidant Capacity (TAC) of 89.50 ± 0.49 mg gallic acid/g and an Iron Reducing Power (IRP) of 79.75 ± 0.49 µg/mL (Table 1; Fig. 2). Table 1In vitro antioxidant activities of the synthesized compounds, expressed as percentage inhibition at 50 µg/mL and median inhibitory concentration (IC50, µg/mL), compared with the ascorbic acid standard.The values were calculated from a sample size of n = 3 and are presented as mean ± SE. Table 1In vitro antioxidant activities of the synthesized compounds, expressed as percentage inhibition at 50 µg/mL and median inhibitory concentration (IC50, µg/mL), compared with the ascorbic acid standard.The values were calculated from a sample size of n = 3 and are presented as mean ± SE. In vitro antioxidant activities of the synthesized compounds, expressed as percentage inhibition at 50 µg/mL and median inhibitory concentration (IC50, µg/mL), compared with the ascorbic acid standard. The values were calculated from a sample size of n = 3 and are presented as mean ± SE. Fig. 2In vitro antioxidant activity of various synthetic compounds compared to ascorbic acid standard. In vitro antioxidant activity of various synthetic compounds compared to ascorbic acid standard. Scavenging activity At a concentration of 50 µg/mL, compounds 5c and 5f showed the highest inhibition rates against DPPH, ABTS, and NO radicals, as indicated in Table 2; Fig. 3a. This suggests strong scavenging activity. Additionally, these compounds exhibited the lowest IC50 values compared to the other compounds studied, as shown in Fig. 3b. Compound 5c shows the highest scavenging activity because of the electron-withdrawing 4-chloro substituent. This group deactivates aromatic rings against radical attack and stabilizes the resulting antioxidant radical through resonance38. Compound 5f exhibits the greatest radical scavenging activity, attributable to the presence of its free nitro (-NO2) group. This functional group facilitates electron and hydrogen donation, thereby neutralizing radicals and conferring resonance stabilization. Furthermore, the nitro group’s capacity to withdraw electrons via both inductive and resonance effects contributes to the stabilization of reaction intermediates, increases electrophilicity, and effectively directs the compound’s radical-scavenging properties39. These compounds exhibited the highest in vitro scavenging activity, with compound 5d showing the most potent inhibition at 45.14 ± 0.81, 48.89 ± 0.81, and 41.14 ± 0.81% and IC50 values of 8.11 ± 0.17, 6.63 ± 0.31, and 9.57 ± 0.15 µg/mL, respectively. Compound 5a also demonstrated significant inhibition at 33.03 ± 0.11, 36.78 ± 0.11, and 29.03 ± 0.11% with IC50 values of 11.08 ± 0.07, 8.79 ± 0.25, and 13.55 ± 0.10 µg/mL, respectively. Compounds 5b and 5e showed similar scavenging activity but had the lowest inhibition percentage and the highest IC50 compared to the other compounds tested. This decrease in antioxidant activity may be due to the presence of 4-methyl (4-CH3) and 4-methoxy (4-OCH3) substitutions, which are known to have lower radical scavenging activity in phenolic compounds because they lack a mobile, dissociable hydrogen atom necessary for effective hydrogen atom transfer to free radicals40. However, at the same concentration, the standard ascorbic acid exhibited the lowest IC50 values (4.91 ± 0.05, 4.13 ± 0.11, and 5.58 ± 0.05 µg/mL, respectively) and the highest inhibition percentage (74.53 ± 0.46, 78.28 ± 0.46, and 70.53 ± 0.46%, respectively). Table 2In vitro free radical scavenging activities of target compounds shown as inhibition percentages (%) at 50 µg/mL concentration and median inhibitory concentrations (IC50, µg/mL) compared to ascorbic acid standard.Scavenging ActivityDPPHABTSNOInhibition.(%)IC50(µg/mL)Inhibition.(%)IC50(µg/mL)Inhibition.(%)IC50(µg/mL) 5a 33.03 ± 0.1111.08 ± 0.0736.78 ± 0.118.79 ± 0.2529.03 ± 0.1113.55 ± 0.10 5b 14.97 ± 0.0724.44 ± 0.1518.72 ± 0.0717.28 ± 0.4810.97 ± 0.0735.87 ± 0.35 5c 63.86 ± 0.095.73 ± 0.0367.61 ± 0.094.78 ± 0.1459.86 ± 0.096.57 ± 0.04 5d 45.14 ± 0.818.11 ± 0.1748.89 ± 0.816.63 ± 0.3141.14 ± 0.819.57 ± 0.15 5e 15.09 ± 0.0724.24 ± 0.1518.84 ± 0.0717.17 ± 0.4711.09 ± 0.0735.48 ± 0.34 5f 64.37 ± 0.095.68 ± 0.0368.12 ± 0.094.75 ± 0.1460.37 ± 0.096.52 ± 0.04 STD (Ascorbic Acid) 74.53 ± 0.464.91 ± 0.0578.28 ± 0.464.13 ± 0.1170.53 ± 0.465.58 ± 0.05The values were calculated from a sample size of n = 3 and are presented as mean ± SE. Table 2In vitro free radical scavenging activities of target compounds shown as inhibition percentages (%) at 50 µg/mL concentration and median inhibitory concentrations (IC50, µg/mL) compared to ascorbic acid standard.Scavenging ActivityDPPHABTSNOInhibition.(%)IC50(µg/mL)Inhibition.(%)IC50(µg/mL)Inhibition.(%)IC50(µg/mL) 5a 33.03 ± 0.1111.08 ± 0.0736.78 ± 0.118.79 ± 0.2529.03 ± 0.1113.55 ± 0.10 5b 14.97 ± 0.0724.44 ± 0.1518.72 ± 0.0717.28 ± 0.4810.97 ± 0.0735.87 ± 0.35 5c 63.86 ± 0.095.73 ± 0.0367.61 ± 0.094.78 ± 0.1459.86 ± 0.096.57 ± 0.04 5d 45.14 ± 0.818.11 ± 0.1748.89 ± 0.816.63 ± 0.3141.14 ± 0.819.57 ± 0.15 5e 15.09 ± 0.0724.24 ± 0.1518.84 ± 0.0717.17 ± 0.4711.09 ± 0.0735.48 ± 0.34 5f 64.37 ± 0.095.68 ± 0.0368.12 ± 0.094.75 ± 0.1460.37 ± 0.096.52 ± 0.04 STD (Ascorbic Acid) 74.53 ± 0.464.91 ± 0.0578.28 ± 0.464.13 ± 0.1170.53 ± 0.465.58 ± 0.05The values were calculated from a sample size of n = 3 and are presented as mean ± SE. In vitro free radical scavenging activities of target compounds shown as inhibition percentages (%) at 50 µg/mL concentration and median inhibitory concentrations (IC50, µg/mL) compared to ascorbic acid standard. STD (Ascorbic Acid) The values were calculated from a sample size of n = 3 and are presented as mean ± SE. Fig. 3In vitro free radical scavenging activities of various synthetic compounds shown as (a) inhibition percentages (%) at 50 µg/mL concentration and (b) median inhibitory concentrations (IC50, µg/mL) compared to ascorbic acid standard. In vitro free radical scavenging activities of various synthetic compounds shown as (a) inhibition percentages (%) at 50 µg/mL concentration and (b) median inhibitory concentrations (IC50, µg/mL) compared to ascorbic acid standard. In vitro anti-diabetic activity Both α-glucosidase and α-amylase are integral to the regulation of blood glucose levels through their enzymatic breakdown of carbohydrates into simple sugars41. The inhibition of α-amylase serves to mitigate postprandial hyperglycemia by impeding the enzymatic conversion of starch into glucose prior to its absorption. α-Glucosidase, an enzyme localized in the small intestine, catalyzes the hydrolysis of disaccharides into glucose molecules42. The inhibitory efficacy of acarbose, a widely prescribed antidiabetic agent, has been assessed in studies focusing on its capacity to suppress the activities of both α-amylase and α-glucosidase43. Additionally, aldose reductase, an enzyme implicated in the pathogenesis of diabetic complications, facilitates the reduction of excess D-glucose to D-sorbitol44. Quercetin has been identified by Dawood et al.45 as a promising candidate for aldose reductase inhibition, suggesting its potential utility as a standard therapeutic agent. Compounds 5c and 5f showed the strongest inhibition of α-amylase, α-glucosidase, and aldose reductase enzymes compared to other compounds at a concentration of 50 µg/mL, with the lowest IC50 values. This is supported by the data in Table 3 and depicted in Fig. 4. This is because the free 4-chloro substituent serves as a non-competitive or mixed-type inhibitor, often exhibiting higher potency than unsubstituted analogs46. The chlorine atom also increases lipophilicity, enhancing the compound’s ability to penetrate cell membranes and bind to enzyme active sites47. Furthermore, the presence of a free nitro (-NO2) group is a crucial structural feature that enhances the inhibitory effect of compounds on carbohydrate-metabolizing enzymes. This group serves as a potent electron-withdrawing group, changing the polarity of molecules and enhancing their ability to bind to the nucleophilic sites of enzymes48,49, showing that compounds with strong antioxidant properties can effectively inhibit carbohydrate-metabolizing enzymes. This dual action is due to their structural features that enable both free radical scavenging and binding to enzyme active sites. The aromatic ring structure facilitates electron delocalization, essential for scavenging free radicals and interacting with aromatic residues like Trp-516 in enzyme binding sites. This connection between antioxidant capacity and enzyme inhibition strength has been confirmed by Balci et al.50, . These compounds showed the highest in vitro anti-diabetic activity, with compound 5d exhibiting the most potent inhibition of α-amylase, α-glucosidase, and aldose reductase enzymes at 46.44 ± 0.69, 40.69 ± 0.69, and 46.79 ± 0.80%, respectively, and IC50 values of 9.09 ± 0.09, 6.71 ± 0.09, and 5.68 ± 0.13 µg/mL. Compound 5a also displayed significant inhibition at 36.07 ± 0.10, 30.32 ± 0.10, and 34.87 ± 0.11%, with IC50 values of 11.70 ± 0.11, 9.00 ± 0.16, and 7.62 ± 0.02 µg/mL, respectively. Compounds 5b and 5e exhibited comparable anti-diabetic activity, with the lowest inhibition percentage on the tested carbohydrate-metabolizing enzymes and the highest IC50 among the compounds tested. The reduced inhibitory effects on enzyme activities may be attributed to the 4-methyl (4-CH3) and 4-methoxy (4-OCH3) substitutions, which diminish hydrogen-bonding capability and decrease the affinity between the inhibitor and the enzyme’s active site. Moreover, the increased lipophilicity could restrict binding interactions51. Methoxylation (4-OCH3) can lower activity by transforming a hydroxyl hydrogen-bond donor into a hydrogen-bond acceptor or a hydrophobic methyl ether52,53 demonstrated that methoxy and methyl groups lack the strong hydrogen-bonding and specific binding properties of hydroxyl groups, leading to reduced binding efficiency to the enzyme’s active site and diminished inhibitory potential. Acarbose showed significant inhibitory effects on α-amylase and α-glucosidase, with inhibition rates of 77.82 ± 0.43 and 72.07 ± 0.43%, respectively, at the same concentration. The IC50 values were 5.42 ± 0.06 µg/mL for α-amylase and 3.79 ± 0.06 µg/mL for α-glucosidase. These results are in line with54, who reported that acarbose, the positive control, had stronger inhibitory effects on these enzymes compared to the studied extracts. Quercetin, a standard drug for aldose reductase, exhibited the highest inhibition percentage (82.88 ± 0.49%) and the lowest IC50 value (3.20 ± 0.02 µg/mL). Table 3In vitro anti-diabetic activity of various synthetic compounds (5a-f) shown as inhibition percentages (%) at 50 µg/mL concentration and median inhibitory concentrations (IC50, µg/mL) the corresponding standard.Anti-diabetic Activityα-Amylaseα-GlucosidaseAldose ReductaseInhibition.(%)IC50(µg/mL)Inhibition.(%)IC50(µg/mL)Inhibition.(%)IC50(µg/mL) 5a 36.07 ± 0.1011.70 ± 0.1130.32 ± 0.109.00 ± 0.1634.87 ± 0.117.62 ± 0.02 5b 20.61 ± 0.0620.48 ± 0.1914.86 ± 0.0618.37 ± 0.3217.09 ± 0.0615.54 ± 0.04 5c 62.47 ± 0.086.76 ± 0.0556.72 ± 0.084.81 ± 0.0865.22 ± 0.094.07 ± 0.02 5d 46.44 ± 0.699.09 ± 0.0940.69 ± 0.696.71 ± 0.0946.79 ± 0.805.68 ± 0.13 5e 20.72 ± 0.0620.37 ± 0.1914.97 ± 0.0618.24 ± 0.3217.21 ± 0.0615.43 ± 0.04 5f 62.90 ± 0.086.71 ± 0.0557.15 ± 0.084.78 ± 0.0865.73 ± 0.094.04 ± 0.02 STD Acarbose Quercetin 77.82 ± 0.435.42 ± 0.0672.07 ± 0.433.79 ± 0.0682.88 ± 0.493.20 ± 0.02 Table 3In vitro anti-diabetic activity of various synthetic compounds (5a-f) shown as inhibition percentages (%) at 50 µg/mL concentration and median inhibitory concentrations (IC50, µg/mL) the corresponding standard.Anti-diabetic Activityα-Amylaseα-GlucosidaseAldose ReductaseInhibition.(%)IC50(µg/mL)Inhibition.(%)IC50(µg/mL)Inhibition.(%)IC50(µg/mL) 5a 36.07 ± 0.1011.70 ± 0.1130.32 ± 0.109.00 ± 0.1634.87 ± 0.117.62 ± 0.02 5b 20.61 ± 0.0620.48 ± 0.1914.86 ± 0.0618.37 ± 0.3217.09 ± 0.0615.54 ± 0.04 5c 62.47 ± 0.086.76 ± 0.0556.72 ± 0.084.81 ± 0.0865.22 ± 0.094.07 ± 0.02 5d 46.44 ± 0.699.09 ± 0.0940.69 ± 0.696.71 ± 0.0946.79 ± 0.805.68 ± 0.13 5e 20.72 ± 0.0620.37 ± 0.1914.97 ± 0.0618.24 ± 0.3217.21 ± 0.0615.43 ± 0.04 5f 62.90 ± 0.086.71 ± 0.0557.15 ± 0.084.78 ± 0.0865.73 ± 0.094.04 ± 0.02 STD Acarbose Quercetin 77.82 ± 0.435.42 ± 0.0672.07 ± 0.433.79 ± 0.0682.88 ± 0.493.20 ± 0.02 In vitro anti-diabetic activity of various synthetic compounds (5a-f) shown as inhibition percentages (%) at 50 µg/mL concentration and median inhibitory concentrations (IC50, µg/mL) the corresponding standard. Fig. 4In vitro anti-diabetic activity of various synthetic compounds shown as: (a) inhibition percentages (%) at 50 µg/mL concentration and (b) median inhibitory concentrations (IC50, µg/mL) compared to donepezil standard. In vitro anti-diabetic activity of various synthetic compounds shown as: (a) inhibition percentages (%) at 50 µg/mL concentration and (b) median inhibitory concentrations (IC50, µg/mL) compared to donepezil standard. Molecular modeling Molecular Docking study The newly synthesized compounds (5a-f) were docked against α-amylase, aldose reductase, and α-glucosidase to evaluate their molecular affinity as promising anti-diabetic agents. In the current work, compound 5f exhibited a promising binding mode with a high affinity score (-8.97 Kcal/mol) against Aldose reductase. Compound 5f showed three polar hydrogen bonds with pharmacophoric amino acids His111 (2.01 and 2.17) and Leu301 (2.97). Moreover, the ligand interaction was established by forming nine hydrophobic π-π, π-anion, π-cation and π-alkyl interactions between the phenyl groups and essential amino acids Trp21, Tyr49, Cys299, Leu301, and Trp112 (Fig. 5). Additionally, the reference ligand complexed with Aldose reductase (IDD594) showed various types of interactions, nine hydrophobic π-π and π-alkyl interactions and supported by three hydrogen bonds and three halogen interactions with essential amino acids Trp112, Tyr49, and His111, with distances of 1.83, 1.64, and 1.79 Å, with an affinity score of -7.41 Kcal/mol. (Fig. 6). Meanwhile, the tested compound 5c demonstrated a good binding pattern of interaction with α-amylase with an affinity score of -7.28 kcal/ mol. Eight hydrophobic π-alkyl, π-anion, and π-π stacked interactions were connected with the hydrophobic sidechains of Lys200, Tyr151, Ile235, His201, Leu162, Asp197, and Asp300. Additionally, three attractive ionic bonds were noted with polar amino acids Asp197, Glu233, and Asp300, supported with one hydrogen bond with crucial amino acid His305 with a distance of 2.90 Å (Fig. 7). On the other hand, compound 5c showed binding affinity of -6.64 kcal/ mol against the α-glucosidase enzyme; the terminal p-chlorophenyl moiety interacted with five π-sulfur, π-alkyl, π-π, and π-anion interactions with Met470, Trp432, Trp329, and Asp568. Additionally, the pyridinyl moiety interacted with Ala628 and Asp630 by π-alkyl and π-anion interactions, supported by two ionic interactions, Asp568 and Asp232 (Fig. 8). Furthermore, the reference ligand (Acarbose), which co-crystalized with α-amylase and α-glucosidase as potent inhibitor with affinity scores of -8.56, and − 7.18 Kcal/mol, respectively, Table 4. (Acarbose) showed many hydrogen bonds with polar amino acids in target pocket of α-amylase, like Thr163, Gln63, Trp59, His101, Asp197, Glu233, Gly306, Glu240, Lys200, His201, Arg195, Asp300, His299, and His305, additionally, acarbose showed the same binding pattern of interaction with α-glucosidase supported with π-interactions with Trp432, Phe601, and Trp329 (Figs. 9 and 10). Fig. 53D figure of the proposed binding mode of Compound 5f against Aldose reductase. Amino acids are colored yellow, and the ligand is colored turquoise. 3D figure of the proposed binding mode of Compound 5f against Aldose reductase. Amino acids are colored yellow, and the ligand is colored turquoise. Fig. 63D figure of the proposed binding mode of the co-crystalized ligand (IDD594) Aldose reductase. Amino acids are colored yellow, and the ligand is colored brown. 3D figure of the proposed binding mode of the co-crystalized ligand (IDD594) Aldose reductase. Amino acids are colored yellow, and the ligand is colored brown. Fig. 73D figure of the proposed binding mode of compound 5c against α-amylase. Amino acids are colored yellow, and the ligand is colored turquoise. 3D figure of the proposed binding mode of compound 5c against α-amylase. Amino acids are colored yellow, and the ligand is colored turquoise. Fig. 83D figure of the proposed binding mode of compound 5c against α-glucosidase. Amino acids are colored yellow, and the ligand is colored turquoise. 3D figure of the proposed binding mode of compound 5c against α-glucosidase. Amino acids are colored yellow, and the ligand is colored turquoise. Fig. 93D figure of the proposed binding mode of Acarbose against α-amylase. Amino acids are colored yellow, and the ligand is colored beige. 3D figure of the proposed binding mode of Acarbose against α-amylase. Amino acids are colored yellow, and the ligand is colored beige. Fig. 103D figure of the proposed binding mode of Acarbose against α-glucosidase. Amino acids are colored yellow, and the ligand is colored beige. 3D figure of the proposed binding mode of Acarbose against α-glucosidase. Amino acids are colored yellow, and the ligand is colored beige. Table 4Molecular Docking results of the tested compound 5c, compound 5f, Acarbose, and reference IDD594 against α-glucosidase, α-amylase, and Aldose reductase.Compd. IDα-glucosidaseα-amylaseAldose reductaseRMSD value (Å)Affinity score (kcal/mol)RMSD value (Å)Affinity score (kcal/mol)RMSD value (Å)Affinity score (kcal/mol) 5c 1.18-6.640.70-7.281.30-7.62 5f 1.59-6.250.92-6.131.61-8.97 Acarbose 1.25-7.181.02-8.56-- IDD594 ----1.16-7.41 Table 4Molecular Docking results of the tested compound 5c, compound 5f, Acarbose, and reference IDD594 against α-glucosidase, α-amylase, and Aldose reductase.Compd. IDα-glucosidaseα-amylaseAldose reductaseRMSD value (Å)Affinity score (kcal/mol)RMSD value (Å)Affinity score (kcal/mol)RMSD value (Å)Affinity score (kcal/mol) 5c 1.18-6.640.70-7.281.30-7.62 5f 1.59-6.250.92-6.131.61-8.97 Acarbose 1.25-7.181.02-8.56-- IDD594 ----1.16-7.41 Molecular Docking results of the tested compound 5c, compound 5f, Acarbose, and reference IDD594 against α-glucosidase, α-amylase, and Aldose reductase. Molecular dynamics (MD) simulation study Molecular dynamics (MD) simulations were performed over 100 ns to evaluate the stability of compound 5f (the top-ranked docking pose) within the aldose reductase (AR) active site. Root-mean-square deviation (RMSD and RMSF) profiles were calculated for both the protein-ligand complex and the ligand relative to their initial positions. Detailed analysis of compound 3f interactions within the binding pocket was subsequently conducted. Protein and ligand RMSD and RMSF analysis Following molecular docking, compound 5f in complex with aldose reductase (AR) was selected for a 100 ns molecular dynamics (MD) simulation. The conformational stability of the protein backbone was evaluated using root-mean-square deviation (RMSD) of Cα atoms (blue line, Fig. 11a) relative to the initial coordinates. As shown in Fig. 11, compound 5f demonstrated robust stability within the AR binding site throughout the simulation, with minor fluctuations observed between ~ 10 ns and ~ 20 ns, followed by stabilization until the endpoint. Notably, the target protein loops, particularly residues 225–235, exhibited significant mobility without disrupting ligand interactions. The protein-ligand complex maintained a stable conformation post-binding, surpassing the pre-interaction stability (Fig. 11b). Overall, the complex achieved equilibrium by the end of the simulation. Fig. 11The RMSD and RMSF of Compound 5f against aldose reductase (AR) over 100 ns. The RMSD and RMSF of Compound 5f against aldose reductase (AR) over 100 ns. Protein ligand interactions analysis Histogram of Protein Ligand Interactions Analysis The target Compound 5f showed a promising binding mode of interactions with crucial amino acids. Compound 3f formed π-interactions with the following residues: Trp21 (~ 40%), Val48 (~ 15%), Trp80 (~ 35%), Trp112 (~ 90%), Phe123 (~ 15%), and Tyr210 (~ 40%), as presented in Fig. 12. Additionally, compound 5f interacted with aldose reductase (AR) by many polar hydrogen bonds and water-bridged H-bond, where crystal water molecules form a link between the protein residues and ligands as showed with residues, Hiss111 (~ 110%), Trp112 (~ 60%), Cys299(~ 90%), Leu301(~ 100%), Cys304(~ 10%), and Tyr310(~ 100%). Fig. 12Histogram analysis describing the binding interactions of Compound 5f with aldose reductase (AR) during the simulation time (100 ns). Histogram analysis describing the binding interactions of Compound 5f with aldose reductase (AR) during the simulation time (100 ns). Interaction timelines were further visualized by plotting contact frequencies over simulation time. Heatmaps (Fig. 13) depict the number of specific interactions formed by compound 5f with (AR) residues per frame, where darker shades represent higher interaction occupancy. Analysis revealed that (AR) conformations sustained up to eight simultaneous contacts with compound 5f. The most persistent interactions involved Trp21, Trp80, His111, Trp112, Tyr210, Cys299, Leu301, and Tyr310. Fig. 13Heat map describing the total interactions within compound 5f with aldose reductase (AR) during the simulation time. Heat map describing the total interactions within compound 5f with aldose reductase (AR) during the simulation time. Conclusion In summary, this investigation successfully designed and synthesized a series of imidazopyridine-based chalcones incorporating a pyridine moiety (5a-f), which demonstrated significant dual antioxidant and antidiabetic activities. Notably, compound 5f was identified as the most promising candidate, exhibiting superior radical-scavenging efficacy across various assays and potent inhibitory effects against the three principal antidiabetic enzymes α-amylase, α-glucosidase, and aldose reductase with IC50 values in the low micromolar range. Molecular docking analyses further supported the strong binding affinity of compound 5f for aldose reductase, which exceeded that of the standard reference inhibitor. In addition, molecular dynamics simulations verified that the protein–ligand complex remained consistently stable throughout a 100-nanosecond simulation period. Taken together, these findings underscore compound 5f as a promising lead candidate deserving further structural refinement and preclinical investigation for the management of oxidative stress-related diabetic complications. Materials and methods Chemistry Melting points were measured using the Electrothermal IA 9000 apparatus, and no corrections were applied to these values. Nuclear magnetic resonance (NMR) analysis, encompassing both 1H and 13C-NMR spectra, was conducted with NMR spectrometers (500 MH, JEOL, JAPAN) located at National Research Centre, Egypt. Mass spectrum (Direct Inlet part to mass analyzer in Thermo Scientific GCMS model ISQ) and Elemental analyses (FLASH 2000 CHNS/O analyzer, Thermo Scientific (USA) were carried out at the Regional Center for Mycology and Biotechnology (RCMB), Al-Azhar University, Nasr City, Cairo. Chemical shifts are reported in δ (ppm), while coupling constants are expressed in Hz. Thin-layer chromatography (TLC) was employed to monitor the reactions, utilizing silica gel on aluminum sheets (60 F254, Merck) with a chloroform/methanol (9.8:0.2 v/v) eluent, which was subsequently visualized using iodine-potassium spray. Compounds 3a-f were previously prepared55. General procedure for the preparation of target compounds 5a-f A solution containing imidazopyridine carboxaldehyde derivatives 3a–f (0.001 mol) [phenyl, 4-methylphenyl, 4-chlorophenyl, 4-bromophenyl, 4-methoxy phenyl and 4-nitro phenyl] and acetylpyridine (4) (0.001 mol) was dissolved in ethanol (15 mL). To this mixture, a catalytic amount of potassium hydroxide (0.002 mol) was added, and the resulting mixture was stirred at ambient temperature for 3–5 h. After the reaction period, the mixture was allowed to cool, and the precipitated solid was collected by filtration. The crude product was then purified by recrystallization from ethanol to afford the desired compounds 5a–f. 3-(2-phenylimidazo[1,2-a]pyridin-3-yl)-1-(pyridin-2-yl)prop-2-en-1-one (5a). Yellow powder, m.p. 179–181 °C, yield (77%). 1H NMR (500 MHz, DMSO-d6): δ = 6.80 (d, 1H, J = 8.0 Hz, H-Ar), 6.98–7.11 (m, 3 H, =CH&H-Ar), 7.27 (t, 1H, J = 7.5 Hz, H-Ar), 7.43 (d, 2 H, J = 9.0 Hz, H-Ar), 7.53–7.66 (m, 4 H, H-Ar), 7.76–7.78 (m, 1H, H-Ar), 7.83 (d, 1H, J = 6.0 Hz, H-Ar), 8.35 (d, 1H, J = 7.0 Hz, H-Ar). 8.48 (d, 1H, J = 8.50 Hz, H-Ar). 8.72 (d, 1H, J = 4.5 Hz, H-Ar). 13C NMR (101 MHz, DMSO-d6) δ = 118.40, 118.45, 118.68, 119.53, 122.27, 128.31, 129.26, 129.36, 130.00, 130.73,131.02, 133.17, 135.12, 135.61, 142.43, 143.79, 144.05, 156.45(C = N), 159.50 (C = N-pyridine), 188.02 (C = O). Analysis for C21H15N3O (325.37), Calcd.: % C, 77.52; H, 4.65; N, 12.91; O, 4.92. Found: % C, 77.64; H, 4.74; N, 12.99. MS m/z (R.A.%): 325 (M+) (13.03%), 46.13 (100.00%). 1-(pyridin-2-yl)-3-(2-(p-tolyl)imidazo[1,2-a]pyridin-3-yl)prop-2-en-1-one (5b). Yellow powder, m.p. 153–154 °C, yield (82%). 1H NMR (500 MHz, DMSO-d6): δ = 2.39 (s,3 H, CH3), 6.58 (d, 1H, J = 8.5 Hz, H-Ar), 6.15–7.19 (m, 2 H, CH&H-Ar), 7.40 (m, 2 H, H-Ar), 7.55 (d, 1H, J = 8.5 Hz, H-Ar), 7.81 (d, 2 H, J = 8.0 Hz, H-Ar), 7.93 (d, 1H, J = 8.5 Hz, H-Ar), 8.14–8.17 (m, 3 H, H-Ar), 8.26 (brs, 2 H, H-Ar). 13C NMR (101 MHz, DMSO-d6) δ = 20.13(CH3), 116.35, 118.39, 118.43, 118.76, 119.22, 119.52, 125.17, 128.28, 130.00, 130.44, 130.55, 133.75, 135.64, 138.84, 142.07, 143.80, 146.40, 156.50, 159.51(C = N-pyridine), 187.99(C = O). Analysis for C22H17N3O (339.39), Calcd.: % C, 77.86; H, 5.05; N, 12.38. Found: % C, 77.99; H, 5.17; N, 12.40. MS m/z (R.A.%): 339 (M+) (32.57%), 239.68 (100.00%). 3-(2-(4-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)-1-(pyridin-2-yl)prop-2-en-1-one (5c). Yellow powder, m.p. 164–166 °C, yield (79%). 1H NMR (500 MHz, DMSO-d6): δ = 6.84 (d, 1H, J = 8.0 Hz, H-Ar), 6.88–6.92 (m, 2 H, =CH&H-Ar), 6.98–7.03 (m, 3 H, H-Ar), 7.30–7.34 (m, 3 H, =CH&H-Ar), 7.22 (d, 2 H, J = 9.0 Hz, H-Ar), 8.19–8.20 (m, 1H, H-Ar), 8.52 (d, 1H, J = 7.0 Hz, H-Ar). 8.78 (d, 1H, J = 4.50 Hz, H-Ar). 13C NMR (101 MHz, DMSO-d6) δ = 116.35, 118.39, 118.43, 118.76, 119.22, 119.52, 128.28, 130.00, 130.44, 130.55, 133.75, 135.64, 138.84, 142.07, 143.80, 146.93, 156.50, 159.51(C = N-pyridine), 187.96 (C = O). Analysis for C21H14ClN3O (359.81), Calcd.: % C, 70.10; H, 3.92; N, 11.68. Found: % C, 70.22; H, 4.02; N, 11.81. MS m/z (R.A.%): 359 (M+) (10.49%), 132.66 (100.00%). 3-(2-(4-bromophenyl)imidazo[1,2-a]pyridin-3-yl)-1-(pyridin-2-yl)prop-2-en-1-one (5d). Yellow powder, m.p. 173–175 °C, yield (86%). 1H NMR (500 MHz, CDCl3): δ = 7.10–7.13 (m, 2 H, =CH & H-Ar), 7.41 (t, 1H, J = 7.5 Hz, H-Ar), 7.48 (t, 1H, J = 6.5 Hz, H-Ar), 7.64–7.96 (m, 5 H, H-Ar), 7.75 (d, 1H, J = 7.0 Hz, H-Ar), 7.86–7.89 (m, 1H, H-Ar), 8.19–8.21 (m, 1H, H-Ar), 8.28 (brs, 1H, H-Ar), 8.74 (d, 1H, J = 6.0 Hz, H-Ar). 13C NMR (101 MHz, CDCl3) δ = 114.85, 118.38, 118.43,118.71, 119.52, 119.71, 127.75, 128.29, 130.00, 130.49, 131.16, 133.55, 135.63, 142.21, 143.78, 144.05, 156.50, 159.50(C = N-pyridine), 187.88(C = O). Analysis for C21H14BrN3O (404.26), Calcd.: % C, 62.39; H, 3.49; N, 10.39. Found: % C, 62.50; H, 3.61; N, 10.52. MS m/z (R.A.%): 404 (M+) (24.86%), 174.03 (100.00%). 3-(2-(4-methoxyphenyl)imidazo[1,2-a]pyridin-3-yl)-1-(pyridin-2-yl)prop-2-en-1-one (5e). Yellow powder, m.p. 148–149 °C, yield (78%). 1H NMR (500 MHz, DMSO-d6): δ = 7.13–7.18 (m, 3 H, =CH & H-Ar), 7.20 (d, 2 H, J = 8.0 Hz, H-Ar), 7.40 (t, 1H, J = 7.0 Hz, H-Ar), 7.51 (t, 1H, J = 7.5 Hz, H-Ar), 7.60–7.62 (m, 3 H, H-Ar), 7.66 (d, 2 H, J = 8.5 Hz, H-Ar), 8.22 (d, 1H, J = 8.0 Hz, H-Ar) 8.57 (d, 1H, J = 8.0 Hz, H-Ar). 13C NMR (101 MHz, DMSO-d6) δ = 55.27(OCH3), 116.26, 116.48, 118.39, 118.44, 118.66, 119.52, 128.31, 130.00, 130.73, 131.56, 131.65, 133.22, 135.61, 142.44, 142.80, 143.78, 156.51, 159.50 (C = N-pyridine), 187.92 (C = O). Analysis for C22H17N3O2 (355.39), Calcd.: % C, 74.35; H, 4.82; N, 11.82. Found: % C, 74.48; H, 4.93; N, 11.92. MS m/z (R.A.%): 355 (M+) (68.22%), 344.92 (100.00%). 3-(2-(4-nitrophenyl)imidazo[1,2-a]pyridin-3-yl)-1-(pyridin-2-yl)prop-2-en-1-one (5f). Yellow powder, m.p. 220–222 °C, yield (67%). 1H NMR (500 MHz, DMSO-d6): δ = 6.67–6.70 (m, 2 H, =CH & H-Ar), 7.06–7.11 (m, 3 H, H-Ar), 7.30 (d, 1H, J = 7.0 Hz, H-Ar), 7.63–7.71 (m, 3 H, H-Ar), 7.78–7.81 (m, 2 H, H-Ar), 8.08 (brs, 1H, H-Ar), 8.59 (brs, 1H, H-Ar), 8.81 (d, 1H, J = 8.5 Hz, H-Ar). 13C NMR (101 MHz, DMSO-d6) δ = 118.60, 119.54, 124.39, 126.35, 128.32, 130.01, 130.24, 130.97, 132.79, 135.61, 141.15, 141.65, 142.81, 143.79, 148.49, 156.53, 159.21(C = N-pyridine), 187.79(C = O). Analysis for C21H14N4O3 (370.36), Calcd.: % C, 68.10; H, 3.81; N, 15.13;. Found: % C, 68.21; H, 3.93; N, 15.25. MS m/z (R.A.%): 370 (M+) (19.64%), 80.03 (100.00%). Biological evaluations In vitro biological activities All biological activity assays were performed in triplicate for each sample. Detailed methodologies are described in the Supplementary Materials. Antioxidant activity The total antioxidant capacity (TAC)56 and iron-reducing power (IRP)57 of the tested compounds were evaluated using ascorbic acid as the reference standard. Scavenging activity The 1,1-Diphenyl-2-picrylhydrazyl (DPPH) scavenging activity of each synthetic compound was evaluated using the method described by Rahman et al.58, to determine the median inhibitory concentration (IC50) and Inhib. %, with ascorbic acid as the positive control. The IC50 and Inhib. % of the 2,2’-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical were determined using the method suggested by Arnao et al.59, . The nitric oxide (NO) radical scavenging activity was measured using the Griess Illosvory reagent reaction as outlined by Chakraborthy60 to determine the Inhib. % and IC50. Anti-diabetic activity The enzyme assays measured the inhibition percentage (%) of α-amylase (Wickramaratne et al., 2016)61 and α-glucosidase enzymes62 using acarbose as the standard drug. The aldose reductase inhibition assay followed the method outlined by Ramu et al. (2014)63 with quercetin as the standard drug. IC50 values for each sample were determined by plotting different sample concentrations against enzyme inhibition percentage to generate a curve. In Silico studies Molecular Docking Analysis In the effort to discover new anti-diabetic candidates, the newly synthesized compounds were docked against α-glucosidase, α-amylase and Aldose reductase target protein obtained from protein data bank (PDB IDS: 3W37, 1B2Y and 2I17) to evaluate their potential affinity64–66. Target protein structures were prepared by removing crystallographic water molecules, protonating the structures, and correcting missing valence atoms. Energy minimization was then performed, after which the structures were saved in PDBQT format. Similarly, the tested compounds underwent protonation, energy minimization, and conversion to PDBQT format before molecular docking against the target active sites using AutoDock Vina version 1.5.767. Top-scoring poses were selected based on binding affinity energies and the pattern of molecular interactions with the crucial amino acids; additionally, 3D/2D visualizations were generated in Discovery Studio 2024 Visualizer68. Docking validity was confirmed by re-docking co-crystallized ligands of α-glucosidase, α-amylase, and Aldose reductase, yielding RMSD values of 1.25, 1.02, and 1.16 Å, respectively69. Molecular dynamics (MD) simulation MD simulations were run in Desmond (Schrödinger) under NPT (300 K, 1 bar) for 100 ns using OPLS_2005, PME electrostatics (9.0 Å cutoff), SPC water, Nosé-Hoover/Martyna–Tuckerman–Klein coupling (2.0 ps), and r-RESPA integrator (frames every 4.8 ps), The behavior and interactions between ligands and proteins were examined using the Simulation Interaction Diagram tool within the Desmond MD package. The stability of MD simulations was assessed by monitoring the root mean square deviation (RMSD) of ligand and protein atom positions over time70,71. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2